What recent performance suggests about LeMaitre Vascular (LMAT)

LeMaitre Vascular (LMAT) has drawn attention after a recent share price of $112.23, alongside a month return of 28% and past 3 months return of 32.1%, putting its recent momentum in focus for investors.

Beyond the recent 28.0% 1 month share price return, LMAT’s 39.9% year to date share price return and 33.4% 1 year total shareholder return suggest momentum has been building over both shorter and longer periods.

If you are weighing LMAT’s recent run and want other ideas in healthcare, it may be worth scanning 36 healthcare AI stocks

With LeMaitre Vascular now trading at $112.23, slightly above a published price target of $111.00 and with a low value score of 1, the key question is whether the recent strength leaves upside on the table or if markets are already pricing in future growth.

Most Popular Narrative: 1.1% Overvalued

With LeMaitre Vascular’s most followed fair value estimate at $111.00 versus the last close of $112.23, the current price sits slightly above that narrative view. This puts the underlying growth story and assumptions under closer scrutiny.

Double digit organic top line growth is a key pillar in bullish models, supporting the view that the current revenue trajectory can justify higher valuation multiples. Material margin expansion, highlighted in recent research, suggests improving profitability that can support higher earnings power over time if execution remains consistent.

Curious what kind of revenue path and margin profile needs to unfold to back that fair value line? The narrative leans on compounding earnings, resilient profitability and a premium earnings multiple that assumes those trends hold together. The exact mix of growth, margins and valuation expectations might surprise you.

Result: Fair Value of $111 (OVERVALUED)

However, there are pressure points to watch, including reliance on price increases and temporary stocking orders, as well as execution risks around international approvals and supply for key products.

Next Steps

With mixed views on risks and rewards already on the table, now is a good time to review the data yourself and pressure test the assumptions behind LMAT’s story using 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If LMAT has your attention, do not stop here; broaden your watchlist now so you are not late to the next opportunity that fits your style.

• Spot potential value opportunities early by scanning companies highlighted in the 49 high quality undervalued stocks and see which ones match your return and risk expectations.
• Prioritise resilience by reviewing the 76 resilient stocks with low risk scores so you can focus on businesses that may better align with your capital preservation goals.
• Hunt for under the radar ideas with the screener containing 27 high quality undiscovered gems and see which names others may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.